
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 21-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg.
Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 21-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg.
6ix hasn’t read this filing yet.
Alembic Pharmaceuticals Limited on 6ix
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals